CY1118081T1 - Παρασκευασματα συνδυασμου με εξωσωματα και κορτικοστεροειδες - Google Patents

Παρασκευασματα συνδυασμου με εξωσωματα και κορτικοστεροειδες

Info

Publication number
CY1118081T1
CY1118081T1 CY20161100969T CY161100969T CY1118081T1 CY 1118081 T1 CY1118081 T1 CY 1118081T1 CY 20161100969 T CY20161100969 T CY 20161100969T CY 161100969 T CY161100969 T CY 161100969T CY 1118081 T1 CY1118081 T1 CY 1118081T1
Authority
CY
Cyprus
Prior art keywords
extractions
corticosteroids
combination preparations
combination therapy
diseases
Prior art date
Application number
CY20161100969T
Other languages
Greek (el)
English (en)
Inventor
Peter Wehling
Julio Reinecke
Original Assignee
Orthogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthogen Ag filed Critical Orthogen Ag
Publication of CY1118081T1 publication Critical patent/CY1118081T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/15Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/19Platelets; Megacaryocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5176Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184Virus capsids or envelopes enclosing drugs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
CY20161100969T 2009-12-10 2016-09-29 Παρασκευασματα συνδυασμου με εξωσωματα και κορτικοστεροειδες CY1118081T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009057495 2009-12-10
PCT/EP2010/069426 WO2011082950A1 (de) 2009-12-10 2010-12-10 Kombinationspräparate mit exosomen und corticosteroid

Publications (1)

Publication Number Publication Date
CY1118081T1 true CY1118081T1 (el) 2017-06-28

Family

ID=43707934

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100969T CY1118081T1 (el) 2009-12-10 2016-09-29 Παρασκευασματα συνδυασμου με εξωσωματα και κορτικοστεροειδες
CY20161100983T CY1118044T1 (el) 2009-12-10 2016-10-04 Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20161100983T CY1118044T1 (el) 2009-12-10 2016-10-04 Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες

Country Status (22)

Country Link
US (3) US9724391B2 (pl)
EP (2) EP2437748B8 (pl)
JP (2) JP5984674B2 (pl)
KR (2) KR101786444B1 (pl)
CN (2) CN107096031A (pl)
AU (2) AU2010340999B2 (pl)
BR (2) BR112012013888A2 (pl)
CA (2) CA2781576C (pl)
CY (2) CY1118081T1 (pl)
DE (1) DE202009017772U1 (pl)
DK (2) DK2437747T3 (pl)
ES (2) ES2594896T3 (pl)
HR (2) HRP20161268T1 (pl)
HU (2) HUE030460T2 (pl)
LT (2) LT2437748T (pl)
MX (2) MX2012006430A (pl)
PL (2) PL2437747T3 (pl)
PT (2) PT2437747T (pl)
RS (2) RS55251B1 (pl)
RU (2) RU2526161C2 (pl)
SI (2) SI2437747T1 (pl)
WO (2) WO2011082951A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170189475A9 (en) * 2009-12-10 2017-07-06 Orthogen Ag Combination preparation comprising a cytokine antagonist and corticosteroid
DE102012019088A1 (de) * 2012-09-28 2014-04-03 Orthogen Ag Antibakterielle Arzneimittelpräparate
CN104673749B (zh) * 2015-02-12 2017-10-20 江苏大学 一种粒细胞样髓源性抑制细胞来源exosomes及其应用
WO2017080668A1 (en) * 2015-11-13 2017-05-18 Orthogen Ag Pharmaceutical preparation effective in age-related disorders
US20190290689A1 (en) * 2016-08-17 2019-09-26 Orthogen Ag Anti-ageing pharmaceutical preparation
AU2017313844B2 (en) 2016-08-19 2023-10-12 University Of Florida Research Foundation, Incorporated Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus
WO2018056481A1 (ko) * 2016-09-23 2018-03-29 ㈜프로스테믹스 면역 억제 및 항염증성 조성물
US11958886B2 (en) 2016-12-07 2024-04-16 University Of Florida Research Foundation, Incorporated IL-1RA cDNAs
CN108175759B (zh) * 2016-12-08 2021-03-19 暨南大学 一种抗肿瘤靶向给药系统及其制备方法与应用
EA038300B1 (ru) * 2017-04-18 2021-08-06 Юниверсити Оф Флорида Рисерч Фаундейшен, Инкорпорейтед Кднк il-1ra
CN108619114B (zh) * 2018-05-02 2020-08-11 东南大学 一种负载地塞米松的巨噬细胞源微囊泡及其制备方法和应用
CN109078171A (zh) * 2018-09-10 2018-12-25 因之彩生物科技(武汉)有限公司 一种外用组合物及其应用以及外用治疗剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2793159A (en) * 1955-03-09 1957-05-21 Upjohn Co Stable hydrocortisone solution
KR0148009B1 (ko) 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
NZ503548A (en) 1996-02-09 2001-09-28 Amgen Inc A fusion protein comprising an IL-1ra receptor antagonist with a constant domain of human immunoglobulin at the carboxy terminus
KR20000070879A (ko) * 1997-02-06 2000-11-25 브루스 엠. 에이센, 토마스 제이 데스로저 인간 에스디에프-5 단백질 및 조성물
US6623472B1 (en) 1997-08-16 2003-09-23 Orthogen Gentechnologic. Gmbh Method for inducing therapeutically-effective proteins
DE19903876B4 (de) 1999-02-01 2006-09-28 Orthogen Gentechnologie Gmbh Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten
DE10213780A1 (de) 2002-03-22 2003-11-27 Orthogen Ag Verfahren und Mittel zur Herstellung therapeutisch interessanter Blutzusammensetzungen
EP1773381A4 (en) 2004-07-01 2008-07-02 Univ Pittburgh Of The Commonwe EXOSOMES IMMUNOSUPPRESSANTS
DE102004036840B4 (de) 2004-07-29 2012-04-19 Orthogen Ag Verfahren und Mittel zur Gewinnung von thrombocytenreichem Plasma
TW200740441A (en) * 2005-06-17 2007-11-01 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
WO2007008155A1 (en) 2005-07-11 2007-01-18 Astrazeneca Ab New combination 1
US7292185B2 (en) * 2005-10-04 2007-11-06 Csi Wireless Inc. Attitude determination exploiting geometry constraints
ZA200804550B (en) * 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
DE102006005016A1 (de) 2006-02-03 2007-08-16 Orthogen Ag Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
AU2010340999A1 (en) 2012-06-21
MX2012006430A (es) 2012-07-30
RU2012128776A (ru) 2014-01-20
RS55251B1 (sr) 2017-02-28
EP2437748B8 (de) 2016-10-19
SI2437748T1 (sl) 2016-12-30
PL2437748T3 (pl) 2017-09-29
RS55217B1 (sr) 2017-02-28
SI2437747T1 (sl) 2016-12-30
KR20120109542A (ko) 2012-10-08
CN102655868A (zh) 2012-09-05
US20130164303A2 (en) 2013-06-27
US9724391B2 (en) 2017-08-08
RU2526161C2 (ru) 2014-08-20
AU2010341000B2 (en) 2014-08-14
EP2437747B1 (de) 2016-08-31
US8828946B2 (en) 2014-09-09
CN102652020A (zh) 2012-08-29
AU2010340999B2 (en) 2014-08-14
ES2594896T3 (es) 2016-12-23
JP5984674B2 (ja) 2016-09-06
CA2781576C (en) 2016-02-09
BR112012014066A2 (pt) 2017-04-04
DE202009017772U1 (de) 2011-04-21
PL2437747T3 (pl) 2017-01-31
EP2437747A1 (de) 2012-04-11
US20190038719A1 (en) 2019-02-07
LT2437747T (lt) 2016-10-25
DK2437747T3 (en) 2016-10-24
JP2013513583A (ja) 2013-04-22
PT2437748T (pt) 2016-10-14
CA2781223C (en) 2016-02-16
US20120237587A1 (en) 2012-09-20
DK2437748T3 (en) 2016-10-24
BR112012013888A2 (pt) 2017-03-07
EP2437747B8 (de) 2016-10-19
LT2437748T (lt) 2016-11-10
HRP20161268T1 (hr) 2016-11-04
MX2012006206A (es) 2012-06-28
CN107096031A (zh) 2017-08-29
US10537614B2 (en) 2020-01-21
RU2012128877A (ru) 2014-01-20
HUE030460T2 (en) 2017-05-29
WO2011082951A1 (de) 2011-07-14
JP5907886B2 (ja) 2016-04-26
CY1118044T1 (el) 2017-05-17
RU2557897C2 (ru) 2015-07-27
EP2437748A1 (de) 2012-04-11
HRP20161279T1 (hr) 2016-12-02
WO2011082950A1 (de) 2011-07-14
AU2010341000A1 (en) 2012-06-21
CA2781576A1 (en) 2011-07-14
JP2013513582A (ja) 2013-04-22
KR20120107108A (ko) 2012-09-28
HUE029979T2 (en) 2017-04-28
EP2437748B1 (de) 2016-08-31
US20120237525A1 (en) 2012-09-20
PT2437747T (pt) 2016-10-18
CA2781223A1 (en) 2011-07-14
ES2594766T3 (es) 2016-12-22
DK2437748T5 (en) 2016-12-05
KR101786444B1 (ko) 2017-10-18

Similar Documents

Publication Publication Date Title
CY1118081T1 (el) Παρασκευασματα συνδυασμου με εξωσωματα και κορτικοστεροειδες
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
MX2015011583A (es) Derivados de amatoxina.
CR20120202A (es) Métodos y composiciones para tratar cáncer
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
UA110370C2 (en) Conjugates of amatoxin with improved linkages
NZ708727A (en) Conjugate compounds
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
BR112012005957A2 (pt) compostos tricíclicos e usos farmacêuticos dos mesmos
BR112012005970A2 (pt) moduladores tricíclicos de proteína quinase
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
GB201209613D0 (en) New compounds
MX350046B (es) Tratamientos para trastornos gastrointestinales.
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
MX2023002599A (es) Conjugados de compuestos de tubulisina cuaternizada.
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
TN2011000647A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria
EA201591925A1 (ru) Терапевтические композиции и их применение
CY1118542T1 (el) Φθορομεθυλ-υποκατεστημενα καρβοξαμιδια πυρρολιου
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
BRPI1006076B8 (pt) composições farmacêuticas
BR112017023539A2 (pt) composições para limpeza de cólon e tratamento de distúrbios gastrointestinais
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.